Is your organisation ready for the ICH E9 (R1) regulatory updates

How will this impact your development programs from a regulatory perspective. Get updates on the FDA guidance on Demonstrating Substantial Effectiveness and on Adaptive Trial Designs for clinical trials.

Venn’s Francois Aubin provides insights on the history, purpose/scope and the framework around these changes.

Click here to read more in the latest Issue #3